Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laninamivir Octanoate in Adults With Chronic Asthma
NCT02022761Phase 1Completed
- Sponsor
- Biota Holdings Limited
- Start
- Oct 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of laninamivir octanoate in influenza (3 arms), sponsored by Biota Holdings Limited. Primary endpoint: Safety and tolerability of single ascending doses at 14 days. Started Oct 2013; status: completed.
02
Drugs
laninamivir octanoate
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02022761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022761.